Ritipenem

Synonym(s): FCE 22101

Class: Beta-lactam (penem)

Spectrum of activity:	Gram-positive  &  Gram-negative
Details of activity:	Broad spectrum antibiotic which demonstrates similar activoty to imipenem, but shows no activity against Pseudomonas aeruginosa
Description:	Intravenous forms and oral form (Ritipenem acoxyl, FCE-22891, prodrug of ritipenem)
Institute where first reported:	Novartis, Switzerland
Year first mentioned:	1986
Highest developmental phase:	Phase 3
Development status:	Inactive
Reason Dropped:	FDA withdrew approval in 2008; high neurotoxicity

Chemical structure(s):
Canonical SMILES:	C[C@H]([C@H]1C(=O)N2C(=C(COC(=O)N)S[C@H]12)C(=O)O)O
Isomeric SMILES:	C[C@H]([C@@H]1[C@@H]2N(C1=O)C(=C(S2)COC(=O)N)C(=O)O)O
InChI:	InChI=1S/C10H12N2O6S/c1-3(13)5-7(14)12-6(9(15)16)4(19-8(5)12)2-18-10(11)17/h3,5,8,13H,2H2,1H3,(H2,11,17)(H,15,16)/t3-,5+,8-/m1/s1
InChI Key:	IKQNRQOUOZJHTR-UWBRJAPDSA-N
Structure link:	https://pubchem.ncbi.nlm.nih.gov/compound/65633

External links:
Guide to Pharmacology:	ritipenem
Citations:	http://jac.oxfordjournals.org/content/20/2/179.full.pdf http://jac.oxfordjournals.org/content/25/3/371.long